Inclusion Criteria:

• * Male or female subject at least 18 years of age
• * Subject is able to provide written informed consent and comply with the requirements of this study protocol
• * Subjects have AKN class I or II (less than 6.5 cm in width)
• * Subjects who are women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and must be practicing an adequate and medically acceptable method of birth control for at least 30 days prior to Day 0 and at least 6 months after the last dose of study. Acceptable methods of birth control include:
• * intrauterine device (IUD) oral;
• * transdermal;
• * implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study);
• * tubal ligation;
• * abstinence;
• * barrier methods with spermicide.
• * If not of child-bearing potential, subjects must have:
• * a sterile or vasectomized partner;
• * have had a hysterectomy;
• * a bilateral oophorectomy or be clinically diagnosed infertile;
• * or be in a menopausal state for at least a year.
• * Subject is judged to be in good general health as determined by the principal investigator.

Exclusion Criteria:

• * unable to understand and provide written consent
• * Have received prior intralesional steroids for AKN within the past 6 months
• * Are using topical steroids or topical medications on their scalp within 4 weeks
• * Have used Duobrii on the scalp for AKN or other scalp disorders
• * Subject is pregnant or breastfeeding
• * Use of prior systemic medication for AKN or acne (doxycycline or isotretinoin) or hair loss in the last 6 months
• * Currently using topical minoxidil or prior use within the past 3 months
• * Have a history of other or other active scalp/hair disease or other forms of or other forms of alopecia
• * Are on systemic steroids or other immunosuppressants
• * Have a history of auto-immune disease, thyroid disorder, or hypersensitivity to steroids.